Translated automatically – community improvements welcome.
Rilmazolam
Rilmazolam is a benzodiazepine with anxiolytic, hypnotic, and muscle-relaxing properties. It acts as a positive allosteric modulator at the GABA-A receptor, leading to enhanced inhibitory neurotransmission. The substance is being pharmacologically investigated for the treatment of anxiety disorders and sleep disturbances. Due to its pharmacological profile, there is a moderate risk of dependence and side effects.
Mechanism of Action
- GABA-A agonist
Names / Identifiers
IUPAC: 8-chloro-6-(2-chlorophenyl)-N,N-dimethyl-4H-[1,2,4]triazolo[1,5-a][1,4]benzodiazepine-2-carboxamide
Mechanism of Action
Rilmazolam acts as an agonist at the GABA-A receptor, leading to increased inhibition of neuronal activity. This can produce anxiolytic and sedative effects.
Effects
Effects described from scientific sources. Individual experiences vary.
Dosage
Individual sensitivity varies. Not a dosage recommendation.
Duration
Risks & Warnings
Warnings
- Pregnancy
- Breastfeeding
- Severe respiratory diseases
Known Risks
- medium
- Mögliche Abhängigkeit und Toleranzentwicklung bei längerem Gebrauch.
Safer Use
- Start at low doses.
- Do not combine with alcohol or other sedatives.
Harm reduction tips do not replace medical advice.
Known Interactions
- Alcohol
- Opioids
- Other benzodiazepines
This list is not exhaustive. Interactions can have unpredictable effects.
Legal Status
Not legal advice. Status may change.